SCHEMBL4928567

SCHEMBL4928567

Oc1cc(O)c(-c2noc3ccccc23)cc1CNc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 9/20 0.50
ESR2 Q92731 9/20 0.50
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HSD17B3 P37058 1/20 0.41
MAOB P27338 4/20 0.41
HIF1A Q16665 1/20 0.41
HSP90AA1 P07900 3/20 0.40
EPHX2 P34913 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4935041 0.90 MAPT (0.51) ESR1ESR2ALDH1A1KDM4EL3MBTL1
SCHEMBL4932010 0.86 MAPT (0.48) ESR1ESR2L3MBTL1KMT2ALMNA
SCHEMBL4928618 0.86 MAPT (0.54) ESR1ESR2ALDH1A1KDM4EL3MBTL1
SCHEMBL4933048 0.79 HIF1A (0.41) ESR1ESR2ALDH1A1KDM4EKMT2A
SCHEMBL4932005 0.79 ESR1 (0.56) ESR1ESR2KDM4ELMNAALOX15
SCHEMBL4933001 0.78 ESR1 (0.52) ESR1ESR2KDM4EHSD17B3HSP90AA1
SCHEMBL4932865 0.75 MAPT (0.50) ESR1ESR2ALDH1A1KDM4EL3MBTL1
SCHEMBL4933522 0.71 ESR1 (0.72) ESR1ESR2HSP90AA1
SCHEMBL4928048 0.71 HSP90AA1 (0.57) ESR1ESR2ALDH1A1KDM4EKMT2A
SCHEMBL4928663 0.69 MAPT (0.45) ESR1ESR2ALDH1A1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer AVENTIS PHARMA S.A. (FR) 2008-03-20 US claimed
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer AVENTIS PHARMA S.A. (FR) 2008-03-20 US disclosed
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer AVENTIS PHARMA S.A. (FR) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer UGT2B7, UGT2B17, CYP4X1 ESR1 2306/4885ESR2 987/4885ALDH1A1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.